A Pilot Study of the Striatal Dopamine Transporter Levels in Kratom-Dependent and Normal Subjects Using 99mTc-TRODAT-1 Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT)

Article

Author: Hashim, Hazlin ; Zulkifli, Nurul Nadiah ; Abdul Hamid, Khadijah ; Zainudin, Norasma Amira Binti ; Mansor, Syahir

OBJECTIVEThe study aims to elucidate the effects of kratom addiction on dopamine transporter (DAT) using [2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-N2,N20,S2,S20]oxo-[1R-(exo-exo)]-[^99mTc] technetium (^99mTc-TRODAT-1) brain single photon emission computed tomography-computed tomography (SPECT-CT) in kratom-dependent and healthy subjects.MATERIALS AND METHODSWe recruited 12 kratom-dependent subjects and 13 healthy men to participate in this study. Addiction, craving, depression, and cognitive scores were assessed. All subjects received a single bolus injection of ^99mTc-TRODAT-1 with 914.1 MBq ± 65.5 of activity (mean ± SD). The brain SPECT-CT images were reconstructed using 3D ordered subset expectation maximization (3D-OSEM) along with attenuation correction (AC), scatter correction (SC), and resolution recovery (RR) with an iteration number of four and a subset of 10. The Cohen's Kappa interrater-reliability between two raters, the standardized uptake value of body weight (SUV_BW), and the asymmetrical index percentage (AI%) were evaluated.RESULTSKappa statistics showed a fine agreement of abnormal ^99mTc-TRODAT-1 uptake in the striatum region for the kratom-dependent group with the κ value of 0.69 (p = 0.0001), and the percentage of agreement for rater 1 and rater 2 was 56% and 64%, respectively. There was a reduction in average SUV in kratom-dependent subjects compared to healthy control subjects in the left caudate and left striatum (0.938 vs. 1.251, p = 0.014, and 1.055 vs. 1.29, p = 0.036, respectively). There was a significant difference in the AI% of the caudate region between the kratom-dependent group and the normal group (33% vs. 14%, p = 0.019).CONCLUSIONOur findings signify that kratom addiction, may cause a change in DAT level and the results can be confirmed using ^99mTc-TRODAT-1 SPECT-CT.

30 Nov 2022·Clinical Psychopharmacology and Neuroscience

Striatal Dopamine Transporter Availability is Associated with Sleep Disturbance among Patients with Bipolar I Disorder: A Single-photon Emission Computed Tomography Study Using [^99mTc] TRODAT-1

Article

Author: Chiu, Nan Tsing ; Yang, Yen Kuang ; Tseng, Huai-Hsuan ; Lu, Tsung-Hua ; Chen, Po See ; Lin, Shih-Hsien

ObjectiveBipolar disorder (BD) is characterized by the poor sleep quality. Whether the striatal dopamine transporter (DAT) availability is related to sleep quality among patients with BD is unclear.MethodsFifty-three euthymic patients with BD (24 BD-I and 29 BD-II) and sixty-eight healthy controls were enrolled. The Chinese Version of the Pittsburgh Sleep Quality Index (PSQI) was used, and the availability of DAT was assessed by single-photon emission computed tomography (SPECT) using [^99mTc] TRODAT-1.ResultsThe sleep disturbance component of the PSQI was significantly associated with the level of DAT availability among patients with BD.ConclusionThe striatal dopaminergic activity that contributes to resilience to adversity was associated with sleep pattern among patients with BD.

01 Mar 2022·Clinical Nuclear MedicineQ3 · MEDICINE

99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable

Q3 · MEDICINE

Article

Author: Huang, Wen-Sheng ; Yu, Tsung-Hsun ; Peng, Nan-Jing ; Chiang, Yung-Hsiao ; Tsai, Chi-Jung ; Yeh, Skye Hsin-Hsien ; Lin, Shinn-Zong

ObjectivesNeuroimaging studies in the past 20 years have documented an age-related decline in striatal dopamine transporters (DATs), which is a marker of dopaminergic neurodegeneration; however, concerns about ethnic variations in the decline in DAT with age have not been addressed. The purpose of this study was to assess the rate of striatal DAT loss in healthy Taiwanese adults using kit-based 99mTc-TRODAT-1, a radioligand for DAT SPECT.Patients and MethodsFifty healthy subjects (mean age ± SD, 63 ± 12 years; range, 30–80 years) were studied. 99mTc-TRODAT-1 was prepared from a lyophilized kit. Brain DAT SPECT imaging was acquired between 165 and 195 minutes postinjection (~740 MBq or 20 mCi) using a dual-head camera equipped with fan-beam collimators (Helix SPX; GE). Specific uptake in the striatum (ST), caudate nucleus (CA), and putamen (PU) were calculated from reconstructed transaxial slices at the level of maximal striatal activity. Occipital cortices were used as reference areas. Data were presented as specific binding ratios.ResultsAge had a significant moderate to large negative effect on striatal DAT, which declined by −25.7% ± 6.10% between the ages of 30 and 80 years, equivalent to 6.4% loss per decade. The rates of decline in the CA and PU were 6.9% and 7.3% per decade, respectively.ConclusionsThis study suggests ethnic variations may not significantly affect the age-related decline in DAT. The data generated in this study could also be used as a reference to estimate DAT loss/occupancy in patients with DAT-related diseases.

100 Deals associated with 99mTc-TRODAT-1

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Contrast agents	Phase 2	-	-	-
Contrast agents	Phase 2	-	University of Pennsylvania	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2019	Not Applicable	-	-	99m Tc-Trodat-1 (Conventional Dual-headed SPECT (C-SPECT))	pginzvwgms(fwdrjbubnz) = Linear correlation of left SBR between CZT- and C-SPECT was y (CZT-SPECT)= 1.0767x(C-SPECT), R^2= 0.5541 and y (CZT-SPECT) = 1.5821x(C-SPECT), R^2=0.6989 for right SBR elolpximyi (zigcubzkeg ) View more	-	21 May 2019
				99m Tc-Trodat-1 (Cardiac-dedicated CZT SPECT (CZT-SPECT))

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

99mTc-TRODAT-1

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation